Veracyte (VCYT) PT, Estimates Bumped at Piper Jaffray Despite Q2 Rev Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip rally offsets renewed Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices slide over 1% as US-Iran conflict clouds Hormuz reopening
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Veracyte (VCYT) Tops Q2 EPS by 2c, Amends Agreement with Sanofi's Genzyme
August 13, 2014 4:12 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.31), $0.02 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $8.7 million versus the consensus estimate of $9.36 million.
The company also announced an agreement to amend terms of its co-promotion agreement with Genzyme... More
